|
|
| |
| Most Discussed Stocks |
 |
|
|
|
| |
|
Stocks >> Stocks Details |
|
CVBT.OB |
| |
|
Coronary Artery Disease |
|
|
|
CARDIOVASCULAR BIOTHERAPEUTICS |
| |
|
CARDIOVASCULAR BIOTHERAPEUTICS (CVBT.OB) focuses
on coronary artery disease. Its lead product candidate, Cardio Vascu-Grow,
is a fibroblast growth factor protein that induces angiogenesis (blood vessel
growth). When injected directly into the heart near affected arteries, Cardio
Vascu-Grow has been shown to help repair the artery and increase blood flow to
the heart. The company hopes to prove that the candidate will also help stroke victims
and diabetes
patients. Chairman, president, and CEO Daniel Montano and Chief
Clinical Officer Thomas Stegmann each own about 25% of the company.
|
| |
| |
| |
| |
| |
| |
|
| |
|
